Edesa Biotechincis A Clinical Stage Biopharmaceutical Company Based In Markhamcanadafounded In 2015The Company Focuses On Developing Innovative Treatments For Inflammatory And Immune Related Diseasesparticularly Targeting Conditions With Significant Unmet Medical Needsedesa Emphasizes Alternatives To Steroids And Jak Inhibitors To Minimize Side Effects Edesa S Product Pipeline Includes Several Promising Candidateseb05 Is A Monoclonal Antibody Currently In Phase 3 Trials For Acute Respiratory Distress Syndromeardsin Covid 19 Patientseb01 Is A Non Steroidal Topical Cream That Has Completed Phase 3 Trials For Chronic Allergic Contact Dermatitisadditionallyeb07 Is In Phase 2 Trials For Pulmonary Fibrosisand Eb06 Targets Vitiligoan Autoimmune Skin Disorderedesa Collaborates With Novimmune Sa And Yissum Research Development Company To Enhance Its Research And Development Efforts The Company Serves Patients With Limited Treatment Options For Autoimmune Skin Disorders And Life Threatening Respiratory Conditionsedesa Is Publicly Traded On Nasdaq Under The Ticker Edsa And Is Committed To Advancing Late Stage Clinical Programs
